

FORM PTO-1449 (modified)
To: U.S. Department of Commerce
(PW FORM PAT-1449)
Patent and Trademark Office

Atty.
Dkt. No.

M#

Client Ref.

282705

Z70495/UST

INFORMATION DISCLOSURE STATEMENT BY APPLICANT

Applicant: HENNEQUIN, Laurent et al

Appln. No.: New Application

09/913020

Filing Date: August 9, 2001

Date: August 9, 2001

Page

1

of

1

Examiner: unassigned

Group Art Unit: unassigned

U.S. PATENT DOCUMENTS

Examiner's Initials*	Document Number	Date MM/YYYY	Name (Family Name of First Inventor)	Class	Sub Class	Filing Date (if appropriate)
	AR					
	BR					
	CR					

FOREIGN PATENT DOCUMENTS

		Document Number	Date MM/YYYY	Country	Inventor Name	English Abstract		Translation Readily Available	
						Enclosed	No	Enclose	No
	DR	WO 96 29301	9/1996	WIPO					
	ER	WO 95 15758	6/1995	WIPO					
	FR	602 851	6/1994	EP					
	GR	WO 97 42187	11/1997	WIPO					
	HR	WO 99 10349	3/1999	WIPO					
	IR	WO 97 22596	6/1997	WIPO					
	JR								
	KR								
	LR								
	MR								

OTHER (Including in this order Author, Title, Periodical Name, Date, Pertinent Pages, etc.)

	NR	HENNEQUIN et al: "Design and Structure-Activity Relationship of a New Class of Potent VEGF Receptor Tyrosine Kinase Inhibitors", J.MED.CHEM.(JMC MAR,0022623); 1999; VOL. 42 (26); PP 5369-389, XP000197180 AstraZeneca Zeneca Pharma Centre de Recherches Z.I. La Pompelle; Reims; 51689; FR							
	OR	BRIDGES et al: "Enantioselective inhibition of the epidermal growth factor receptor tyrosine kinawse by 4-(.alpha.-phenethylamino)quinazolines" BIOORG.MED.CHEM (BMECEP, 09680896); 1995; VOL. 3 (12)PP 1651-6, XP002134974 Parke-Davis Pharmaceutical Research Division; Ann Arbor; 48105; MI; USA (US)							
	PR	GIBSON et al: "Epidermal growth factor receptor tyrosine kinase: structure-activity relationships and antitumor activity of novel quinazolines" BIOORG.MED.CHEM LETT. (BMCle8, 0960894X); 1997; VOL.7 (21)PP 2723-2728, XP002134975 Zeneca Pharmaceuticals; Research Dep. Cancer, Metabolism and Endocrine; Alderley Park, Macclesfield, Cheshire; SK10 4TG; UK (GB)							
	QR								
	RR								
	SR								

Examiner

Date Considered:

*EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to Applicant.